New article in BioStock: CombiGene comments on recent progress

Interviews and presentations 2020 2021   2020   2019   2018   2017   2016   2015 CombiGene has recently raised more than SEK 25 million through two successful warrants, which were excercised at 98.4 percent. At the same time, CombiGene's two gene therapy projects...

read more

BioStock analyzes CombiGene

News 2020 2021   2020   2019   2018   2017   2016   2015 BioStock today publishes its first analysis of CombiGene. In the analysis, BioStock writes, among other things: "Given the progress CombiGene has made so far, the company is an attractive target for possible...

read more

CombiGene AB (publ): Nominating committee

Regulatory news 2020 2021   2020   2019   2018   2017   2016   2015 The nominating committee has been constituted in accordance with the resolution adopted by the annual general meeting (“AGM”) 2020 The AGM 2020 resolved that a nominating committee should be appointed...

read more

Horizon 2020 continues to invest in CombiGene´s epilepsy project

Regulatory news 2020 2021   2020   2019   2018   2017   2016   2015 On 15 May 2018, CombiGene announced that Horizon 2020 – EU’s Framework Programme for Research and Development – is investing EUR 3.36 million in CombiGene’s continued development and commerzialisation...

read more

Interim Report January – September 2020

Regulatory news 2020 2021   2020   2019   2018   2017   2016   2015 Interim Report January – September 2020 for CombiGene AB (publ)för CombiGene AB (publ) About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the...

read more

Ingeneious #4 2020, News from CombiGene

Ingeneious 2020 2021   2020   2019   2018   2017 Read CombiGene´s newsletter Ingeneious in EnglishTo Ingeneious >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through...

read more

Production platform tested

News 2020 2021   2020   2019   2018   2017   2016   2015 This is an article from Ingeneious number 4 2020.Read the whole Ingeneious here >>   All pharmaceutical productions are performed under a strict regulatory framework called Good Manufacturing Practice or...

read more

Concluding preclinical studies

News 2020 2021   2020   2019   2018   2017   2016   2015 This is an article from Ingeneious number 4 2020.Read the whole Ingeneious here >> Since 2014, CombiGene has conducted a number of preclinical studies that have moved the epilepsy project CG01 forward. All...

read more

December 8-10, 2nd Gene Therapy for Neurological Disorders 2020

News 2020 2021   2020   2019   2018   2017   2016   2015 Gene Therapy for Neurological Disorders deals with the latest development in gene therapy for treatment of diseases of the central nervous system. For CombiGene, it is of course important to follow progress in...

read more

November 2-5 , World Orphan Drug Congress Europe

News 2020 2021   2020   2019   2018   2017   2016   2015 https://www.terrapinn.com/conference/world-orphan-drug-congress/index.stm 2021 » News » Regulatory news » Financial reports » Interviews and presentations » Ingeneious 2020 » News » Regulatory news » Financial...

read more

February 10-11, Swiss Nordic Bio 2021

News 2020 2021   2020   2019   2018   2017   2016   2015 Swiss Nordic Bio is a high-level partnering and investor conference aimed at connecting healthcare innovations, investor and industry. The conference is the number one platform that gathers life...

read more

New article about CombiGene in Biostock

Interviews and presentations 2020 2021   2020   2019   2018   2017   2016   2015 Biostock summarizes the latest news from CombiGene and talks to CEO Jan Nilsson about the importance of the many milestones and the continued plan for the epilepsy project CG01....

read more

Updated analysis of CombiGene

Regulatory news 2020 2021   2020   2019   2018   2017   2016   2015 Analysguiden has today updated its analysis of CombiGene. You can find the result here: https://www.aktiespararna.se/analysguiden/article/796368 2021 » News » Regulatory news » Financial reports...

read more

High pressure at CombiGene!

News 2020 2021   2020   2019   2018   2017   2016   2015 This is an article from Ingeneious number 3 2020. Read the whole Ingeneious here >> Let me begin this text by expressing my and CombiGene’s very great appreciation to all who participated in the warrants...

read more

Ingeneious #3 2020, News from CombiGene

Ingeneious 2020 2021   2020   2019   2018   2017 Read CombiGene´s newsletter Ingeneious in EnglishTo Ingeneious >> 2021 » News » Regulatory news » Financial reports » Interviews and presentations » Ingeneious 2020 » News » Regulatory news » Financial reports...

read more

CombiGene Chairman Bert Junno interviewed in BioStock

Interviews and presentations 2020 2021   2020   2019   2018   2017   2016   2015 CombiGene's Chairman of the Board Bert Junno is interviewed about what attracted him to CombiGene, how he sees the company’s strategy and future and upcoming milestones. Read the...

read more

Meet CombiGene at Gene Therapy Analytical Europé September 1-3

News 2020 2021   2020   2019   2018   2017   2016   2015 As more and more gene therapies approach clinical studies and medical use, a stronger focus on analytical assays for quality control of the production of gene therapies is seen. One example of this is the Gene...

read more

Interim Report January – June 2020

Regulatory news 2020 2021   2020   2019   2018   2017   2016   2015 Interim Report January – June 2020 for CombiGene AB (publ) >> 2021 » News » Regulatory news » Financial reports » Interviews and presentations » Ingeneious 2020 » News » Regulatory news...

read more

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

 

CombiGene AB, Medicon Village, SE-223-81 Lund

 

Linked In     Twitter      Facebook